Negotiated prices are impacting market access and revenue for major pharmaceutical companies like Pfizer, UCB, Bristol-Myers Squibb, and Novartis.

The entities involved

• Pfizer →

  American multinational pharmaceutical and biotechnology corporation

  • Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Mon 05:00
  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
• UCB →

  biopharmaceutical company headquartered in Brussels, Belgium

  Nothing else this week.

• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
  • FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09
• Novartis →

  Swiss-American multinational pharmaceutical corporation

  • Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
  • GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16

Related events

• CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Aug 19